Key Takeaways
- Vivici launched Vivitein™ LF, a precision-fermented lactoferrin ingredient, in the U.S.
- Ingredient aims to address historical supply and cost constraints associated with lactoferrin
- Vivitein™ LF targets gut health, performance recovery, and iron utilization
- Vivici secured self-affirmed GRAS status in the United States
- Product expands Vivici’s Vivitein™ portfolio following Vivitein™ BLG
Vivici Introduces Precision-Fermented Lactoferrin
Dutch ingredients company Vivici has launched Vivitein™ LF in the U.S. market, introducing a precision-fermented lactoferrin ingredient designed to overcome traditional supply and cost limitations.
Lactoferrin, a whey protein often referred to as “pink gold,” has historically been difficult to scale due to its low natural abundance in milk. Vivici stated that Vivitein™ LF addresses these constraints by using precision fermentation to produce high-purity lactoferrin suitable for commercial application.
The ingredient is positioned for use in health and wellness products, particularly those focused on gut health, performance recovery, and sustained vitality.
Functional Benefits and Market Positioning
Vivitein™ LF is designed to support microbiome balance and strengthen the gut barrier. According to the company, the protein may also assist in managing inflammatory responses related to repeated physical activity and in mobilizing iron to improve utilization in the body.
The launch comes amid growth in the global health and wellness food market, which was valued at approximately $938 billion in 2024 and is projected to reach $2.2 trillion by 2032.
“The question that will define the health and wellness industry for years to come, is how can we help the body’s own system maintain health from within,” said Stephan van Sint Fiet, CEO of Vivici. “Innovators who effectively fulfill this unmet consumer demand with innovative and transformative health products leveraging breakthrough proteins, such as Vivitein™ LF, will succeed.”
Vivici has obtained self-affirmed GRAS (Generally Recognized as Safe) status in the U.S. for Vivitein™ LF, enabling commercialization in the American market.
Expanding the Vivitein™ Portfolio
Vivitein™ LF is the second product launched under Vivici’s Vivitein™ brand, following Vivitein™ BLG, a beta-lactoglobulin ingredient previously commercialized by the company.
Founded in 2023, Vivici focuses on developing functional protein ingredients through precision fermentation. The company stated it is expanding its manufacturing footprint to support a global supply network and accelerate market access across regions.
Vivici will showcase Vivitein™ LF and Vivitein™ BLG at Expo West in Anaheim, California, from March 4–6, 2026.
